San Francisco - While pulmonologists can rely on objective tests, such as the pulmonary function test, to assess lung diseases, dermatologists have only subjective assessments of common skin conditions such as atopic dermatitis (AD). A commonly used clinical measure for AD today, SCORAD, relies on subjective criteria in assessing the severity of lesions and the extent of involvement.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.